Patient Risk Should Not Sway Process Validation Decision-Making - Sulzer
This article was originally published in The Gray Sheet
Patient risk should not be used as a factor in determining whether a medical device firm's manufacturing process should be validated as the Global Harmonization Task Force Study Group 3's draft "Process Validation Guidance" suggests, Sulzer Medica says in Aug. 13 comments to FDA.
You may also be interested in...
House and Senate Democrats sponsor legislation to authorize FTC enforcement against sales of "consumer goods and services at an unconscionably excessive price during the" COVID-19 pandemic. "It’s outrageous that some companies and individuals are taking advantage of consumers by price-gouging," says Energy and Commerce Committee Chairman Frank Pallone.
Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.
A US National Academies meeting on digital health technology showcased the communication gap between regulators and tech developers when it comes to important concepts like “digital biomarkers.”